Clinical Trial Update: An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 [Phase 3]

View source ↗

Summary

Open-label extension study of certolizumab pegol in Chinese patients with rheumatoid arthritis who participated in a Phase 3 trial (RA0044).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB Pharma SA | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2018-10-16